ArticleTurkish journal of medical sciences2025
Impact of concurrent parathyroid adenoma on the recurrence of differentiated thyroid carcinoma: a retrospective study.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: The impact of concurrent parathyroid adenoma in differentiated thyroid carcinoma remains unclear. This study compared the recurrence rates of patients operated on for differentiated thyroid carcinoma with concomitant parathyroid adenoma and those operated on for thyroid carcinoma without detected parathyroid adenoma. Materials and methods: This retrospective study examined 340 patients who underwent total thyroidectomy for thyroid carcinoma at our institution. We compared patients with concurrent parathyroid adenoma to those without, assessing clinical, laboratory, surgical, and histopathological findings and thyroid carcinoma recurrence over a 6-year postoperative period. Results: Among all patients, 53/340 (16%) were identified with parathyroid adenoma and were predominantly over the age of 50 years (p < 0.00). There was a significant difference between patients with and without parathyroid adenoma regarding the preoperative serum Ca level (11.21 ± 0.41 mg/dL versus 9.5 ± 0.36 mg/dL, respectively), preoperative serum P level (2.3 ± 0.3 mg/dL versus 3.7 ± 1.4 mg/dL, respectively), and preoperative serum PTH level (142 ± 89.3 pg/mL versus 53.7 ± 11.5 pg/mL, respectively) (p < 0.001 overall). Residual thyroid tissue was detected in 215/340 (63%) patients, and a significant difference existed between patients with parathyroid adenoma (20/53, 38%) and without it (195/287, 68%) (p < 0.00). No significant differences were observed in surgical and/or tumor characteristics between patients with and without parathyroid adenoma. Conclusion: Our findings suggest that parathyroid adenoma has no direct impact on the recurrence of differentiated thyroid carcinomas in the short term. However, our small cohort size limits the generalizability of these results, indicating a need for further studies with larger patient populations and longer follow-up durations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.